3 weeks ago
13
Keith Noonan, The Motley Fool
Sun, August 2, 2026 astatine 12:04 PM CDT 3 min read
Teva Pharmaceutical (NYSE: TEVA) banal closed retired the past week of trading with important gains, rising astir 12.3% crossed the stretch. The S&P 500 gained 0.2% implicit the aforesaid period, and the Nasdaq Composite was up astir 0.5%.
Teva published its second-quarter study aft the marketplace closed connected July 29, posting mixed results. While net for the play came successful beneath Wall Street's target, the institution delivered immoderate quality that excited investors.
Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »
Teva's Q2 results astatine a glimpse
With its Q2 report, Teva announced non-GAAP (adjusted) net of $0.02 per stock -- a show that fell acold abbreviated of the mean expert estimate's telephone for adjusted net per stock of $0.11 successful the period. Meanwhile, income successful the play came successful astatine $4.1 cardinal and surpassed the mean expert people by astir $70 million. The generic cause leader's gross was inactive down astir 1% twelvemonth implicit twelvemonth successful the period, but the diminution was softer than expected -- and investors saw committedness successful the company's guidance and a important caller improvement for the stock.
What's adjacent for Teva?
For the full-year period, Teva is guiding for adjusted net to beryllium betwixt $1.91 per stock and $2.11 per stock aft accounting for closing and administrative costs stemming from its acquisition of Emalex. Meanwhile, the mean expert estimation had called per-share net of $2.16 for the year. The institution besides guided for income to travel successful betwixt $16.5 cardinal and $16.85 billion. For reference, the mean Wall Street estimation had targeted income of $16.63 billion.
With its Q2 report, Teva besides announced that it was gearing up to person its banal listed straight connected the New York Stock Exchange. As portion of the initiative, the Israel-based company's American depositary receipts (ADRs) are acceptable to beryllium replaced with recently listed communal stock. The caller communal banal is acceptable to commencement trading connected September 14, and the nonstop listing could assistance pull enactment from organization investors and retail traders.
Should you bargain banal successful Teva Pharmaceutical Industries close now?
Before you bargain banal successful Teva Pharmaceutical Industries, see this:
The Motley Fool Stock Advisor expert squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Teva Pharmaceutical Industries wasn't 1 of them. The 10 stocks that made the chopped could nutrient monster returns successful the coming years.
English (CA) · 
English (US) · 
Spanish (MX) ·